title: Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study.
abstract: Results obtained in 22 patients with Parkinson's disease in whom treatment with standard Madopar was replaced by Madopar HBS, a CR formulation of the same product, are presented. All the patients presented with dyskinesia and akinesia phenomena related in part to the L-dopa treatment and in part to the disease itself. In 20 patients replacement of the standard agent by HBS led to a distinct improvement in the clinical condition and a significant reduction of the 'on-off' phenomenon. However, with the new formulation the dosage had to be increased by 86% on average as compared with standard Madopar. In 6 of the 22 patients treatment with the HBS formulation has continued for over 6 months and is still giving very good results.
authors.affiliation: Department of Neurology, Vicenza Hospital, Italy.
authors.forename: G P
authors.initials: GP
authors.lastname: Nordera
authors.forename: A
authors.initials: A
authors.lastname: Lorizio
authors.forename: P
authors.initials: P
authors.lastname: Lion
authors.forename: C
authors.initials: C
authors.lastname: Durisotti
authors.forename: G
authors.initials: G
authors.lastname: D'Andrea
authors.forename: F
authors.initials: F
authors.lastname: Ferro-Milone
mesh_terms: D000328:Adult; D000368:Aged; D001545:Benserazide / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy / Q000209:etiology; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D003692:Delayed-Action Preparations; D004338:Drug Combinations; D006834:Hydrazines; C005177:benserazide, levodopa drug combination; D007980:Levodopa; D001545:Benserazide